Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9793858 | 0.79 | BLM (0.35) | POLBKDM4EMEN1KMT2A | |
| SCHEMBL7547751 | 0.79 | BLM (0.35) | POLBKDM4EMEN1KMT2A | |
| SCHEMBL7267577 | 0.78 | BLM (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL2077054 | 0.76 | SMN1; SMN2 (0.36) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL29626913 | 0.74 | MMP12 (0.37) | POLBTSHRSMN1; SMN2 | |
| SCHEMBL2075653 | 0.73 | ALDH1A1 (0.39) | POLBTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL2075651 | 0.73 | ALDH1A1 (0.39) | POLBTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL12808706 | 0.72 | MMP12 (0.49) | POLBTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL817744 | 0.72 | MMP12 (0.49) | POLBTSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13680239 | 0.71 | ACP3 (0.36) | POLBKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810967-B1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INT INC (TW) | 2014-07-30 | — | — | EP | disclosed |
| US-8030514-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2011-10-04 | — | — | US | disclosed |
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | CHIROGLATE INTERNATIONAL INC. | 2009-12-03 | — | — | US | disclosed |
| US-7626024-B2 | Processes and intermediates for the preparations of prostaglandins | Irogate International Inc. (CN) | 2009-12-01 | — | — | US | disclosed |
| US-7626024-B2 | Processes and intermediates for the preparations of prostaglandins | Irogate International Inc. (CN) | 2009-12-01 | — | — | US | disclosed |
| US-7582779-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2009-09-01 | — | — | US | disclosed |
| US-7511168-B2 | Processes and intermediates for the preparations of prostaglandins | Wei, Shih-Yi (TW) | 2009-03-31 | — | — | US | disclosed |
| US-7511168-B2 | Processes and intermediates for the preparations of prostaglandins | Wei, Shih-Yi (TW) | 2009-03-31 | — | — | US | disclosed |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| EP-1810967-A1 | Processes and intermediates for the preparations of prostaglandins | Chirogate International Inc. (TW) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | PTGES, PTGER1, PTGIS | POLB 2593/4885KDM4E 2828/4885TSHR 2650/4885 |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | POLB 2593/4885KDM4E 2828/4885TSHR 2650/4885 |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | POLB 2593/4885KDM4E 2828/4885TSHR 2650/4885 |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | POLB 2593/4885KDM4E 2828/4885TSHR 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.